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ReportEnhanced Proteolysis of -Amyloid in APP
Transgenic Mice Prevents Plaque Formation,
Secondary Pathology, and Premature Death
(Eckman et al., 2003; Farris et al., 2003; Iwata et al.,
2001; Miller et al., 2003). Whether genetic defects in one
or another of these proteases can actually initiate AD
is unknown, although several laboratories have recently
reported evidence of genetic linkage and/or allelic asso-
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Department of Neurology ciation of the IDE gene to conventional (late-onset) AD
in various populations (Ait-Ghezala et al., 2002; BertramBrigham and Women’s Hospital
Harvard Medical School et al., 2000; Edland et al., 2003; Prince et al., 2003).
Whether or not A-degrading proteases are ultimately2Center for Aging, Genetics,
and Neurodegeneration implicated in causing AD, chronic upregulation or disin-
hibition of one of these proteases, using various strate-Massachusetts General Hospital and
Department of Neurology gies, including small molecule activators, represents an
attractive but unexplored therapeutic approach. Com-Harvard Medical School
Boston, Massachusetts 02115 pounds that inhibit the - or -secretases that generate
A have been identified and are being prepared for clini-
cal trials, and an immunotherapeutic approach using A
vaccination has undergone initial evaluation in humansSummary
(for review, see Selkoe and Schenk, 2003). As both of
these strategies have significant theoretical and practi-Converging evidence suggests that the accumulation
of cerebral amyloid -protein (A) in Alzheimer’s dis- cal risks, the alternative strategy of enhancing A degra-
dation ought to undergo rigorous preclinical evaluationease (AD) reflects an imbalance between the produc-
tion and degradation of this self-aggregating peptide. to determine whether it is a safe and efficacious ap-
proach for lowering A in man. To this end, we haveUpregulation of proteases that degrade A thus re-
presents a novel therapeutic approach to lowering examined the consequences in mice of enhancing the
activities of either IDE or NEP, the two A-degradingsteady-state A levels, but the consequences of sus-
tained upregulation in vivo have not been studied. Here proteases that have received the most experimental con-
firmation. Our results show that chronically upregulatingwe show that transgenic overexpression of insulin-
degrading enzyme (IDE) or neprilysin (NEP) in neurons the activity of either protease in neurons results in strik-
ing decreases in brain A levels, plaque formation andsignificantly reduces brain A levels, retards or com-
pletely prevents amyloid plaque formation and its as- its associated cytopathology, and premature death in
APP transgenic mice, in the absence of detectable ad-sociated cytopathology, and rescues the premature
lethality present in amyloid precursor protein (APP) verse effects.
transgenic mice. Our findings demonstrate that chronic
upregulation of A-degrading proteases represents Results
an efficacious therapeutic approach to combating
Alzheimer-type pathology in vivo. We generated transgenic mice overexpressing human
IDE or NEP using a promoter with developmentally de-
Introduction layed, neuron-specific expression (CaM kinase II; May-
ford et al., 1996; Figure 1A). From among numerous
Alzheimer’s disease (AD) is the most prevalent example potential founder animals, we obtained two stable
of a class of human neurodegenerative disorders that mouse lines, one that expressed2-fold IDE (2xIDE) and
involves progressive accumulation of misfolded,  sheet- another that expressed 8-fold NEP (8xNEP), relative
rich proteins (Caughey and Lansbury, 2003). Genetic to nontransgenic littermate controls, as determined by
mutations that increase the production or stability of quantitative Western blotting and protease activity
these proteins result in accelerated and severe forms assays (see below). The higher-fold increase in protease
of the disorders, signifying that accumulation of the pro- expression attained in the 8xNEP transgenic line is likely
teins in the nervous system can actually cause the re- due to lower basal (endogenous) levels of brain NEP
spective clinical syndromes. In the case of AD, the than IDE and also to more efficient translation of the
mechanisms of A production, including the effects of NEP transgene, because the human NEP cDNA contains
causative mutations in the APP and presenilin genes, a better Kozak consensus sequence for translation initi-
have received great attention, whereas far less is known ation than does the IDE cDNA (Kozak, 1986). Consistent
about how A is normally degraded and cleared (Selkoe, with the latter explanation, the 2xIDE transgenic line
2001). Among the proteases that have been found to be was found to express 4 times more transgene RNA
capable of degrading A in vitro, several (IDE, NEP, than the 8xNEP transgenic mice, as judged by real-time
and endothelin-converting enzyme-1 and -2) have been RT-PCR using primers common to the two transgenes
confirmed via genetic deletion in mice to contribute to (data not shown).
the regulation of endogenous brain A levels in vivo To examine the consequences for A accumulation
and amyloid plaque formation, the 2xIDE and 8xNEP
transgenic mice were each crossed to transgenic mice*Correspondence:dselkoe@rics.bwh.harvard.edu
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Figure 1. Generation and Characterization of IDE and NEP Transgenic Mice
(A) Construction of the IDE and NEP transgenes and overview of experimental design. Littermates expressing only the mutant APP transgene
were used as controls.
(B) Western blot analysis of IDE, NEP, full-length APP, and APP carboxy-terminal fragments in the 2xIDEAPP and 8xNEPAPP transgenic
mice and littermate APP transgenic controls.
(C) IDE activity in 2xIDEAPP transgenic mice () versus controls () as determined by 125I-A degradation (Farris et al., 2003). Open symbols
show degradation in the presence of 25 M insulin, a strong competitive inhibitor of IDE.
(D) NEP activity in 8xNEPAPP transgenic mice () versus controls (), as determined by DAGPNG degradation. Open symbols show
degradation in the presence of 20 nM thiorphan, a strong NEP inhibitor.
(E) Survival of transgenic mice. The premature death present in APP transgenic mice () is significantly reduced in 2xIDEAPP () and
8xNEPAPP () transgenic mice at 6 months of age (*p  0.0345 and 0.0348 by Fisher exact test for 2xIDEAPP and 8xNEPAPP transgenic
mice versus APP transgenic mice, respectively; n  16–71 mice per condition). All mice are littermates derived from the same crosses.
overexpressing high levels of human APP harboring founded by the fact that the vast majority of A-degrading
activity in these brain membrane samples is attributableboth the KM670/671NL (“Swedish”) and the V717F
(“Indiana”) AD-causing mutations (Mucke et al., 2000; to IDE. We therefore used the more selective and well-
characterized NEP substrate DAGPNG (Florentin et al.,Figure 1A). The degree of overexpression of each prote-
ase in the crossed mice was determined by quantitative 1984) and determined that NEP activity was increased
700% in the 8xNEPAPP mice relative to controlsWestern analysis on amino acid-analyzed brain mem-
brane fractions (Figure 1B). Interestingly, a small but (Figure 1D). These functional assays thus closely reflect
the relative increases in the respective proteins we ob-statistically significant decrease in endogenous IDE lev-
els was observed in the 8xNEPAPP transgenic mice served by Western blotting.
APPSwe/Ind single transgenic mice raised in our colony(normalized densitometry values of 0.70  0.15 in the
8xNEPAPP transgenic mice versus 1.00 0.04 in APP suffer an abnormally high rate of premature death (6
months) that cosegregates with the APP transgene.transgenic controls; p  0.05 by two-tailed Student’s t
test), and a similar, albeit nonsignificant, decrease in Such premature lethality is not unique to APPSwe/Ind mice,
having been observed in other APP transgenic mouseNEP levels was present in some IDE transgenic mice
(Figure 1B). These results raise the possibility of cross- models (e.g., Hsiao et al., 1995; D. Games and D. Schenk,
personal communication). Remarkably, the incidence ofregulation between the two proteases, perhaps medi-
ated by a common substrate. Importantly, the levels of premature death at 6 months of age was significantly
attenuated in the 2xIDEAPP and the 8xNEPAPPfull-length APP and APP carboxy-terminal fragments
(C83 and C99) were unchanged in the 2xIDEAPP and transgenic mice relative to their APP transgenic lit-
termate controls (Figure 1E). The fact that this effect8xNEPAPP transgenic mice, excluding a detectable
effect of these proteases on the 	-, -, and -secretase was observed following upregulation of two different
A-degrading proteases that otherwise are not believedprocessing steps (Figure 1B).
Using a well-characterized iodinated A degradation to have substrates in common strongly suggests that
progressive A build-up is responsible for the enhancedassay, we confirmed that the 2xIDEAPP mice had an
100% increase in insulin-inhibitable A-degrading ca- mortality observed in our APP transgenic mice. More-
over, the fact that premature death can occur as earlypacity in isolated, washed brain membranes compared
to their APP transgenic littermates (Figure 1C). 8xNEP- as 3 months of age (Figure 1E), well prior to plaque
deposition (see also Hsiao et al., 1995), implies that theAPP mice also exhibited a large increase in thiorphan-
inhibitable A degradation using this assay (data not responsible A species are soluble.
To determine the effects of protease overexpressionshown), although accurate quantification was con-
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Figure 2. Decreased A Levels in the 2xIDEAPP and 8xNEPAPP Transgenic Mice versus APP
Transgenic Controls
(A–D) Cerebral concentrations of soluble (A and C) and insoluble (B and D) AX-40 (A and B) and AX-42 (C and D). Data are mean  SEMs
from age-matched 6- to 10-month-old mice (*p  0.05; n  8 mice per condition).
(E) Degradation of naturally secreted A species by IDE and NEP. Note that both proteases preferentially degrade monomeric A.
(F and G) Levels of soluble endogenous AX-40 (F) and AX-42 (G) are decreased in 2- to 3-month-old 2xIDE and 8xNEP single transgenic
mice relative to nontransgenic controls (*p  0.05 by one-tailed Student’s t test; n  6 2xIDE and nontransgenic mice; n  3 8xNEP mice).
on A accumulation, we quantified cerebral A levels 2A–2D) shows definitively that IDE is localized to cellular
compartments relevant to A degradation in vivo. Givenin 6- to 10-month-old mice using a sensitive and specific
ELISA (Johnson-Wood et al., 1997). Soluble and insolu- that only1%–2% of endogenous IDE protein is associ-
ated with membranes and therefore physically capableble AX-40 and AX-42 brain levels were significantly
decreased by 50% and 90% in the brains of the of interacting with A (Duckworth et al., 1998), it is re-
markable that a mere doubling of this subpopulation2xIDEAPP and 8xNEPAPP crossed transgenic mice,
respectively, relative to APP transgenic controls (Fig- leads to a 
50% reduction in brain A burden in this
particular AD mouse model, which harbors an10,000-ures 2A–2D). Consistent with data from gene-targeted
animals (Farris et al., 2003; Iwata et al., 2001; Miller et fold increase in A over endogenous mouse brain levels
(Mucke et al., 2000). These results indicate that relativelyal., 2003), the finding that soluble A levels are reduced
in the crossed mice, particularly the X-40 forms that are small changes in the activity of IDE and other A-degrad-
ing proteases can dramatically impact steady-state cere-less prone to aggregation, suggests that IDE and NEP
are acting at the level of soluble, monomeric A species, bral A levels, suggesting that modest increases in pro-
teolytic clearance of A in humans might be sufficientprior to overt deposition. To examine this issue more
thoroughly, we added recombinant IDE or NEP to condi- to effect significant changes in the overall economy of
brain A.tioned medium containing both monomeric as well as
oligomeric A species naturally secreted from cells ov- In agreement with the ELISA data, A plaque burden
was decreased 50% in the 2xIDEAPP double trans-erexpressing APP (Walsh et al., 2002a); consistent with
previous reports (Figure 6 of Qiu et al., 1997; Figure 3e genic mice (Figures 3A and 3D) relative to age-matched
APP transgenic littermate controls (Figures 3B and 3E).of Walsh et al., 2002a), IDE degraded A monomers but
not oligomers, and NEP showed a similar preference Strikingly, A plaques were essentially completely ab-
sent in 8xNEPAPP double transgenic mice up to 14(Figure 2E). To assess the effects of IDE and NEP overex-
pression on monomeric A in vivo, in the absence of months of age (Figures 3C and 3F), with only the smallest
hint of diffuse A immunoreactivity evident in a subsetplaque deposition, we quantified endogenous murine
A levels in 2- to 3-month-old 2xIDE and 8xNEP single of animals (see Figure 3C, inset). The decrease in extra-
cellular Adeposition was accompanied by correspond-transgenic mice (i.e., not crossed to APP transgenics).
The two transgenic lines each showed significant reduc- ing reductions in multiple markers of secondary pathol-
ogy, including astrocytosis (as marked by a GFAPtions in steady-state levels of soluble AX-40 and AX-
42 that correlated with the magnitude of A burden in antibody; Figures 4A–4C), dystrophic neurites (as marked
by the 8E5 APP antibody that detects altered periplaqueAPP transgenic crosses (Figures 2F and 2G), providing
strong evidence that the proximal effect of these prote- neurites; Figures 4D–4I), and microgliosis (as marked by
a CD-45 antibody; Figures 4J–4L).ases is to reduce steady-state levels of monomeric A.
Whereas NEP is well known to be a membrane- It is of special interest that chronic neuronal overex-
pression of IDE or NEP beginning postnatally did notanchored, cell-surface protease (Saito et al., 2003;
Turner, 1998), the subcellular localization of IDE has itself have obvious deleterious consequences. Mice ex-
pressing only the 2xIDE or 8xNEP transgenes were bornremained controversial despite reports documenting the
presence of a portion of IDE molecules on the surface in the expected Mendelian ratios, were healthy and fer-
tile, and showed no overt phenotypic abnormalities.of neurons and other cell types (Seta and Roth, 1997;
Vekrellis et al., 2000). Our finding that overexpression Careful neuropathological analysis revealed no detect-
able differences between the brains of the proteaseof IDE reduces both soluble and insoluble A (Figures
Neuron
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Figure 3. Decreased A Plaque Burden in
2xIDEAPP and 8xNEPAPP Transgenic
Mice versus Controls
(A–F) A immunoreactivity in the brains of
8-month-old (A–C) and 14-month-old (D–F)
transgenic mice. Plaque burden is greatly de-
creased in 2xIDEAPP transgenic mice (A
and D) relative to APP transgenic littermate
controls (B and E) and is essentially absent
in 8xNEPAPP transgenic mice (C and F).
The inset in (C) shows the very light A immu-
noreactivity detected in a subset of 8xNEP
APP mice. Shown are brain sections repre-
senting the median degree of pathology at
each time point as judged by two indepen-
dent observers from among 8 to 12 mice
per condition.
transgenic mice and their nontransgenic littermates oligomeric or higher-order A assemblies (Qiu et al.,
1997; Saito et al., 2003; Turner, 1998; Walsh et al., 2002a;(data not shown).
Figure 2E) has raised questions about the potential ther-
apeutic utility of A-degrading enzymes. Indeed, lentivi-Discussion
ral overexpression of NEP in the brains of adult APP
transgenic mice was recently found to only partiallyWork from several laboratories, including ours, has in-
creasingly implicated A oligomers rather than mono- lower A deposition (Marr et al., 2003), leaving open the
possibility that existing aggregates and/or a subset ofmers or mature amyloid fibrils as the species principally
responsible for cell toxicity and neuronal dysfunction in newly generated A molecules might exist that are im-
pervious to degradation by A-degrading proteasesvarious experimental models of AD and in the human
disease itself (Gong et al., 2003; Hsia et al., 1999; Mucke (Walsh et al., 2000, 2002a). However, our finding that
transgenic overexpression of NEP essentially com-et al., 2000; Selkoe, 2002; Walsh et al., 2002a, 2002b).
It appears that relatively stable oligomeric intermediates pletely prevented A deposition and downstream pa-
thology in an APP transgenic mouse with particularlyin A fibrillogenesis are initially formed intracellularly
and are released in part into the extracellular space, high levels of AX-42 (Mucke et al., 2000) is consistent
with the concept that the pathway leading from A pro-where further aggregation into fibrous polymers may
occur (Walsh et al., 2000, 2002a). The fact that IDE and duction to neuronal dysfunction necessarily includes a
protease-sensitive monomeric phase and suggests thatNEP preferentially degrade monomeric species and not
Figure 4. A-Mediated Secondary Pathology
(A–C) Astrocytosis is greatly reduced in the
cortex and hippocampus of 14-month-old
2xIDEAPP (A) and 8xNEPAPP (C) trans-
genic mice, relative to age-matched APP lit-
termate controls (B).
(D–I) Reduction of neuritic dystrophy in the
hippocampus of 2xIDEAPP (D and G) and
8xNEPAPP transgenic mice (F and I) versus
controls (E and H). Dystrophic neurites were
detected with 8E5, an antibody raised against
the APP ectodomain, and visualized at 2.5
(D–F) and 20 (G–I) magnification.
(J–L) Reduced microgliosis in the hippocam-
pus of 2xIDEAPP (J) and 8xNEPAPP (L)
transgenic mice relative to APP transgenic
controls (K). Shown are serial sections from
the same 14-month-old mice selected for Fig-
ures 3D–3F.
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Experimental Procedurestherapies selectively targeting monomeric A species
ought to be sufficient to prevent the development of
AnimalsAD-type pathology in vivo. However, because IDE and
Full-length cDNAs encoding unaltered human IDE or NEP (transcript
NEP each have a number of substrates, the present variant 1) were cloned into a vector containing the 5 regulatory
study cannot exclude the possibility that increased pro- region of the CaMKII gene, an upstream artificial intron, and a down-
stream SV40 polyadenylation signal (gift of J. Shen). The transgenicteolysis of substrates other than A could somehow
constructs were microinjected into the male pronucleus of C57Bl/6influence A deposition and/or its downstream conse-
single-cell embryos, which were implanted into pseudopregnantquences.
Swiss-Webster foster dames. Founder mice were identified fromWhat about mature amyloid deposits that already ex-
tail DNA and further characterized by Southern blotting to confirm
ist at the time of initiation of A protease activation? that each transgenic was integrated at a single locus in each line,
While upregulation of IDE or NEP would not remove A as described previously (LaFerla et al., 2000). Routine genotyping
was performed by PCR using either IDE-Seq0 (5-TTGATACCATTGaggregates directly, the sharp decrease in Amonomer
GCCAGCTCTAG-3) or NEP-Seq0 (5-GTCGAGTCCATCGCTGT-3)levels would be expected to lead to gradual disaggrega-
together with the common primer CaMKII Fwd: (5-GGGATCCACTtion of polymers into monomers under an equilibrium
AGTTCTAGAGCG-3). APPSwe/Ind transgenic mice (Mucke et al., 2000;reaction and the subsequent clearing of the liberated
J20 line; gift of Lennart Mucke, Gladstone Institute, UCSF) were
monomers by the protease. It is also plausible that other maintained on a hybrid background (C57Bl/6  DBA2) and geno-
endogenous clearance mechanisms might be sufficient typed by PCR, as described previously (Games et al., 1995; Mucke
et al., 2000). All mice in the study were F1 progeny derived from ato clear preformed aggregates once monomer levels fall
single cross between the J20 line and NEP or IDE transgenic mice.and the burden of ongoing A deposition decreases. In
For biochemical analysis, mice were anesthetized with Avertin,support of the latter possibility, lesions of the perforant
and their brains were removed, divided sagittally, and snap frozen.pathway that prevent APP delivery to and A deposition
For immunohistochemical analysis, one brain hemisphere was post-
in the hippocampus lead to a striking removal of preex- fixed in 10% phosphate-buffered formalin for 2 hr, washed in phos-
isting A deposits (Lazarov et al., 2002). phate-buffered saline, pH 7.4 (PBS), dehydrated, and embedded in
paraffin, as described (Weiner et al., 2000). These studies wereIt is important to emphasize that our study provides
approved by the Harvard Medical School Standing Committee onno information about the relative roles of NEP and IDE
Animals.in the normal regulation of cerebral A levels nor does
it speak to their relative efficacies as therapeutics. This
ELISA of Cerebral Ais because the stable mouse lines we happened to gen-
To extract soluble cerebral A, frozen cerebrums were homogenized
erate had very different degrees of elevation of the re- in 5 volumes (w:v) 50 mM Tris-HCl, pH 7.4, and centrifuged at
spective proteases. Indeed, it is a principal message of 100,000  g for 1 hr, and the resulting supernate was retained as
our work that it may make little difference which the soluble fraction. To extract Tris-insoluble A, the resulting pellet
was dissolved in 5 volumes (v:v) of 6 M guanidine hydrochloride,A-degrading protease is chosen as a therapeutic tar-
incubated at room temperature for 30 min, and spun at 100,000 get, since it is already known that several are capable
g for 1 hr. ELISAs were performed as described (Johnson-Wood etof degrading A in vivo (Eckman et al., 2003; Farris et
al., 1997; Weiner et al., 2000). We used antibodies that recognize
al., 2003; Iwata et al., 2001; Miller et al., 2003). Therefore, species referred to as X-40 and X-42, which are heterogeneous A
one could choose to pursue this strategy by focusing on peptides that begin anywhere in the amino-terminal region of A
that A-degrading protease the upregulation of which is and end at either residue 40 or 42.
associated with the least adverse effects.
Protease Activity AssaysFrom a therapeutic perspective, upregulation of A
Brain homogenates were prepared as described above, in the ab-degradation appears to compare favorably to clearance-
sence of protease inhibitors. After centrifugation at 100,000  g forbased therapeutics in mice based on immunization
1 hr, the membrane pellet was washed in PBS and recentrifuged
against A. While A-directed immunotherapies have two times. For some preparations, nonintegral membrane proteins
proven effective in removing brain A in mouse models were removed by washing in 100 mM Na2CO3 (pH 11.3), as described
(Bard et al., 2000; DeMattos et al., 2001; Hock et al., (Farris et al., 2003). Absolute protein concentrations were deter-
mined by amino acid analysis, and 125I-A degradation assays were2002; Schenk et al., 1999; Weiner et al., 2000), and per-
performed as described (Leissring et al., 2003). NEP activity was alsohaps even in blunting cognitive decline in some AD pa-
quantified using the NEP-specific fluorogenic peptide substrate,tients (Hock et al., 2003), this approach has also trig-
N-dansyl-D-Ala-Gly-p-(nitro)-Phe-Gly (DAGPNG; Sigma; Florentin et
gered deleterious immune-mediated reactions in a al., 1984). Briefly, 50 g brain membrane protein was incubated with
subset of patients (Nicoll et al., 2003). Based on the 50 M DAGPNG and 20 M elanapril (Sigma) dissolved in 0.5 ml
present findings, we propose that pharmacological Tris-HCl, pH 7.4, with or without 20 nM thiorphan. At each time
point, 100 l aliquots were diluted in 0.4 ml Tris-HCl, pH 7.4, andupregulation of a single A-degrading protease (e.g.,
immediately boiled to terminate proteolytic activity. Following cen-either IDE or NEP) might achieve the same therapeutic
trifugation at 3000  g for 5 min, the supernatant was removed,benefit, while avoiding potentially adverse immune re-
and fluorescence (340 nm excitation, 520 nm emission) was read
sponses. Furthermore, such an approach would have on a Victor2 multilabel plate reader (PerkinElmer). All activity assays
the special advantage of acting catalytically to remove were determined at 37C.
A, rather than stoichiometrically, as antibodies do. The
finding that chronic upregulation of these proteases was Immunohistochemistry
Nine-micrometer brain sections were deparaffinized through anot accompanied by detectable adverse effects in mice
graded alcohol series and washed in PBS. Endogenous peroxidaseup to 14 months of age suggests that additional pre-
activity was quenched by pretreatment with a 3% hydrogen perox-clinical studies of the safety and efficacy of a proteolytic
ide/methanol solution for 25 min. Sections were blocked in 10%
approach are worthy of pursuit. We are currently screen- normal goat serum for 30 min, washed, and incubated with primary
ing compound libraries for small molecules that could antibodies in 3%BSA/PBS overnight at 4C in a humid chamber.
After washing in PBS, the sections were incubated with the appro-activate the IDE-mediated degradation of A.
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priate biotinylated secondary antibody for 30 min. The tissues were burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad.
Sci. USA 98, 8850–8855.washed once again and developed using the avidin/biotin/HRP/DAB
colorimetric method (ABC Elite Kit; Vector Labs; Burlingame, CA). Duckworth, W.C., Bennett, R.G., and Hamel, F.G. (1998). Insulin
Sections were counterstained with Harris hematoxylin, dehydrated, degradation: progress and potential. Endocr. Rev. 19, 608–624.
and affixed with coverslips. All brain sections chosen for staining
Eckman, E.A., Watson, M., Marlow, L., Sambamurti, K., and Eckman,
were on a similar sagittal plane and contained approximately the
C.B. (2003). Alzheimer’s disease beta-amyloid peptide is increased
same area of hippocampus. Serial sections from each animal were
in mice deficient in endothelin-converting enzyme. J. Biol. Chem.
stained with each of the following antibodies: our pAb DW14 (1:2500)
278, 2081–2084.
for human A detection (Walsh et al., 2002a); mAb GFAP (1:500;
Edland, S.D., Wavrant-De Vriese, F., Compton, D., Smith, G.E., Ivnik,Sigma, St. Louis, MO) for detection of reactive astrocytes; mAb 8E5
R., Boeve, B.F., Tangalos, E.G., and Petersen, R.C. (2003). Insulin(1:10,000; gift from Elan Pharmaceuticals) reactive for full-length
degrading enzyme (IDE) genetic variants and risk of Alzheimer’shuman APP, for detection of dystrophic neurites; and mAb anti-
disease: evidence of effect modification by apolipoprotein E (APOE).CD45 (1:5000; Serotec Ltd, Oxford, UK), for detection of microglia.
Neurosci. Lett. 345, 21–24.The degree of amyloid pathology in the transgenic mice was as-
sessed semiquantitively by two independent observers in a blinded Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A.,
fashion, using two sagittal brain sections per mouse (1 mm apart) Frosch, M.P., Eckman, C.B., Tanzi, R.E., Selkoe, D.J., and Guenette,
stained in parallel for A in a total of 8 to 12 mice per transgenic line. S. (2003). Insulin-degrading enzyme regulates the levels of insulin,
amyloid beta-protein, and the beta-amyloid precursor protein intra-
cellular domain in vivo. Proc. Natl. Acad. Sci. USA 100, 4162–4167.Western Blotting
Florentin, D., Sassi, A., and Roques, B.P. (1984). A highly sensitiveWestern blots were performed as described (Farris et al., 2003),
fluorometric assay for “enkephalinase,” a neutral metalloendopepti-using amino acid-analyzed brain membrane protein from the same
dase that releases tyrosine-glycine-glycine from enkephalins. Anal.animals used for the immunohistochemistry, AELISA, and protease
Biochem. 141, 62–69.activity assays. Antibodies used for Western blots included IDE-1
(Vekrellis et al., 2000), 8E5, and C8 (reactive with the carboxy termi- Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P.,
nus of APP), and the following anti-NEP antibodies: 56C6, CD10(C- Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et
17), CD10(N-14), CD10(H-321) (Santa Cruz Biotechnology, Inc.), and al. (1995). Alzheimer-type neuropathology in transgenic mice over-
NEP11-A (Alpha Diagnostic Intl.). Densitometric analyses were per- expressing V717F beta-amyloid precursor protein. Nature 373,
formed using the AlphaEase software package according to the 523–527.
manufacturer’s recommendations (Alpha Innotech Corp.). Immuno-
Gong, Y., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch,precipitation of A and incubations with recombinant proteases
C.E., Krafft, G.A., and Klein, W.L. (2003). Alzheimer’s disease-were performed as described (Walsh et al., 2002a). Recombinant
affected brain: Presence of oligomeric A{beta} ligands (ADDLs) sug-NEP was the generous gift of Guy Boileau and Philippe Crine. Re-
gests a molecular basis for reversible memory loss. Proc. Natl. Acad.combinant IDE was generated as described (Leissring et al., 2003).
Sci. USA 100, 10417–10422.
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